Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>AbbVie has demonstrated a robust financial performance in the second quarter of 2024, affirming the company's strong positioning in the biopharmaceutical industry.</li><li>Under the new leadership of CEO Rob Michael, AbbVie has experienced a promising trajectory with several of its key products and pipeline developments standing out.</li><li>However, as with any investment, there are a multitude of factors to consider, including challenges that might influence future performance.</li></ul>

AbbVie has demonstrated a robust financial performance in the second quarter of 2024, affirming the company's strong positioning in the biopharmaceutical industry.Under the new leadership of CEO Rob Michael, AbbVie has experienced a promising trajectory with several of its key products and pipeline developments standing out.However, as with any investment, there are a multitude of factors to consider, including challenges that might influence future performance.

AbbVie Inc.: Recent Acquisitions & The Expansion of Immunology Portfolio Yielding Results? - Major Drivers

Research from ACF Equity Research, ACF Equity Research

ACF Equity Research

Research from ACF Equity Research

Accuracy | Clarity | Foresight

ACF was set up to improve the effectiveness of capital markets for smaller and mid-sized companies. The majority of jobs are created by smaller companies not global companies. If we can help improve companies use of capital markets more projects will be completed, more jobs created, more global GDP grown, which in turn helps create more resources for education, leading to equality and opportunity for those who are still oppressed by ignorance and poverty.

ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.

We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.

Our independent research is designed to educate our professional investor readers about your company, with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.

We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.

Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.

<ul><li>Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential.</li><li>In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital.</li><li>Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms.</li></ul>

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential.In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital.Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms.

Abbvie Inc - Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

<ul><li>Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results.</li><li>The financial results and current business outlook reflect the strength and momentum of AbbVie's diversified pharmaceutical portfolio, which is projected to have long-term growth prospects.</li><li>The company reported adjusted earnings per share of $2.31 and total net revenues of $12.3 billion, exceeding expectations by $400 million.</li></ul>

Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results.The financial results and current business outlook reflect the strength and momentum of AbbVie's diversified pharmaceutical portfolio, which is projected to have long-term growth prospects.The company reported adjusted earnings per share of $2.31 and total net revenues of $12.3 billion, exceeding expectations by $400 million.

AbbVie Inc.: Acquisition of Landos Biopharma to Enhance Autoimmune Disease Treatments & Other Major Developments

<ul><li>AbbVie Inc.</li><li>showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations.</li><li>The company's growth platform, independent of their iconic Humira, reported full-year sales growth exceeding 8%.</li></ul>

AbbVie Inc.showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations.The company's growth platform, independent of their iconic Humira, reported full-year sales growth exceeding 8%.

AbbVie Inc: Produodopa's Green Light In Scotland & 6 Other Major Developments - Key Drivers

Global Healthcare Analyst

Tina Banerjee

Sun Pharmaceutical Industries / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sun-pharmaceutical-industries-limited" target="_blank" data-smartkarma-citation="entities:98:1" rel="noopener">Sun Pharmaceutical Industries (SUNP IN)</a> Q2FY25 net profit jumped 28% YoY to INR30B on 11% YoY growth in revenue. U.S. and India formulation businesses grew 22% and 11%, YoY, respectively.</li>
<li>Due to deferral of clinical trials of some specialty products, the company has cut R&amp;D investment guidance by 200bps to 7–8% of revenue for FY25 from earlier 8–10%.</li>
<li>With Leqselvi launch becoming uncertain and few others still in late-stage trials, there is no immediate driver to accelerate specialty business momentum.</li>
</ul>



Sun Pharmaceutical Industries (SUNP IN) Q2FY25 net profit jumped 28% YoY to INR30B on 11% YoY growth in revenue. U.S. and India formulation businesses grew 22% and 11%, YoY, respectively.
Due to deferral of clinical trials of some specialty products, the company has cut R&amp;D investment guidance by 200bps to 7–8% of revenue for FY25 from earlier 8–10%.
With Leqselvi launch becoming uncertain and few others still in late-stage trials, there is no immediate driver to accelerate specialty business momentum.


Sun Pharmaceutical (SUNP IN): Q2 Result Beats Estimate; Specialty Business to Face Growth Challenge

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbvie Inc (ABBV US)

AbbVie Inc.: Recent Acquisitions & The Expansion of Immunology Portfolio Yielding Results? - Major Drivers

AbbVie has demonstrated a robust financial performance in the second quarter of 2024, affirming the company's strong positioning in the...

Baptista Research

Abbvie Inc - Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation...

ACF Equity Research

AbbVie Inc.: Acquisition of Landos Biopharma to Enhance Autoimmune Disease Treatments & Other Major Developments

Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results. The financial results and current...

Baptista Research

AbbVie Inc: Produodopa's Green Light In Scotland & 6 Other Major Developments - Key Drivers

AbbVie Inc. showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations. The company's...

Baptista Research

Sun Pharmaceutical (SUNP IN): Q2 Result Beats Estimate; Specialty Business to Face Growth Challenge

Sun Pharma Q2FY25 net profit was up 28% YoY on 11% revenue growth. FY25 R&D investment guidance cut due to deferred clinical trials. Specialty...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

AbbVie Inc.: Recent Acquisitions & The Expansion of Immunology Portfolio Yielding Results? - Major Drivers

AbbVie has demonstrated a robust financial performance in the second quarter of 2024, affirming the company's strong positioning in the...

Baptista Research

Abbvie Inc - Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation...

ACF Equity Research

AbbVie Inc.: Acquisition of Landos Biopharma to Enhance Autoimmune Disease Treatments & Other Major Developments

Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results. The financial results and current...

Baptista Research

AbbVie Inc: Produodopa's Green Light In Scotland & 6 Other Major Developments - Key Drivers

AbbVie Inc. showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations. The company's...

Baptista Research

Sun Pharmaceutical (SUNP IN): Q2 Result Beats Estimate; Specialty Business to Face Growth Challenge

​Sun Pharma Q2FY25 net profit was up 28% YoY on 11% revenue growth. FY25 R&D investment guidance cut due to deferred clinical trials. Specialty...

Tina Banerjee

Sun Pharma Q2FY25 net profit was up 28% YoY on 11% revenue growth. FY25 R&D investment guidance cut due to deferred clinical trials. Specialty...